Cargando…

Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)

OBJECTIVES: MTX, LEF and SSZ are conventional synthetic DMARDs (csDMARDs) with a well-established role in the treatment of RA. We aimed to estimate and compare the relative risks for adverse events (AEs) and the discontinuation of these drugs owing to AEs. METHODS: We included all 3339 patients from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mielnik, Pawel, Sexton, Joseph, Fagerli, Karen M, Bakland, Gunnstein, Hu, Yi, Kristianslund, Eirik K, Hoff, Mari, Wierød, Ada, Kvien, Tore K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Concise Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329773/ https://www.ncbi.nlm.nih.gov/pubmed/37431434 http://dx.doi.org/10.1093/rap/rkad053

Ejemplares similares

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
por: Olsen, Inge C, et al.
Publicado: (2019)

What do we measure with 28-joint DAS in elderly patients? An explorative analysis in the NOR-DMARD study
por: van Onna, Marloes, et al.
Publicado: (2020)

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
por: Gehin, Johanna Elin, et al.
Publicado: (2019)

What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?
por: Nakafero, Georgina, et al.
Publicado: (2021)

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs
por: Brkic, Alen, et al.
Publicado: (2022)

Differential effects of leflunomide and methotrexate on cytokine production in RA
por: Kraan, MC, et al.
Publicado: (2003)

Toxic Epidermal Necrolysis-Like Lesions as Cutaneous Manifestation of Acute Methotrexate Toxicity
por: Singh, Raju, et al.
Publicado: (2020)

Effect of discontinuing ongoing education and postprescription feedback on antimicrobial prescriptions at discharge from the emergency department
por: Tagashira, Yasuaki
Publicado: (2022)

Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis
por: Shashikumar, N.S., et al.
Publicado: (2010)

Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
por: Narváez, Javier, et al.
Publicado: (2015)

Combination of Methotrexate and Leflunomide Is Efficient and Safe for 60 Patients with Rheumatoid Arthritis
por: Chen, Fang, et al.
Publicado: (2022)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Taking off the gown: Impact of discontinuing contact precautions for extended-spectrum β-lactamase (ESBL)–producing organisms
por: Gottlieb, Lindsey B., et al.
Publicado: (2021)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

A pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis
por: Starace, Michela, et al.
Publicado: (2022)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis
por: Wu, Chunling, et al.
Publicado: (2020)

Reasons for discontinuing urate-lowering treatment in community-dwelling adults with gout: results of a primary care-based cross-sectional study
por: Elmelegy, Dalia, et al.
Publicado: (2021)

Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate
por: Lee, Sang-Won, et al.
Publicado: (2012)

Leflunomide/methotrexate: Visceral leishmaniasis and SARS-CoV-2 infection: case report
Publicado: (2022)

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
por: Uhlig, Till, et al.
Publicado: (2022)

Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study
por: Uhlig, Till, et al.
Publicado: (2021)

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)
por: Brkic, Alen, et al.
Publicado: (2023)

Cardiovascular disease risk profiles in inflammatory joint disease entities
por: Wibetoe, Grunde, et al.
Publicado: (2017)

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
por: Uhlig, Till, et al.
Publicado: (2021)

Discontinuing methotrexate to enhance vaccine response
por: Medeiros-Ribeiro, Ana C., et al.
Publicado: (2022)

Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project
por: Ikdahl, Eirik, et al.
Publicado: (2018)

Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance
por: Lin, Mengxin, et al.
Publicado: (2019)

Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report
por: Pliquett, Rainer Ullrich, et al.
Publicado: (2020)

Comparative treatment of Sulfasalazine+Ezetimibe combination and Sulfasalazine in a rat model with induced colitis
por: Jaafar, Farrah Rasool, et al.
Publicado: (2023)

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
por: Gremese, Elisa, et al.
Publicado: (2019)

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
por: Uhlig, T., et al.
Publicado: (2022)

Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis
por: Nossent, Johannes C., et al.
Publicado: (2019)

IL-1A gene variation in relation to cytokine levels and clinical characteristics in ankylosing spondylitis
por: Nossent, Johannes C., et al.
Publicado: (2019)

IL23R gene variants in relation to IL17A levels and clinical phenotype in patients with ankylosing spondylitis
por: Nossent, Johannes C, et al.
Publicado: (2018)

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
por: Takeuchi, Tsutomu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dtu2bfum4vrecigeuh36b1levq